MA55799A - Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 - Google Patents
Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2Info
- Publication number
- MA55799A MA55799A MA055799A MA55799A MA55799A MA 55799 A MA55799 A MA 55799A MA 055799 A MA055799 A MA 055799A MA 55799 A MA55799 A MA 55799A MA 55799 A MA55799 A MA 55799A
- Authority
- MA
- Morocco
- Prior art keywords
- aprmilast
- combination therapies
- therapies including
- tyk2 inhibitors
- tyk2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/029772 WO2020222773A1 (en) | 2019-04-30 | 2019-04-30 | Combination therapies comprising apremilast and tyk2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55799A true MA55799A (fr) | 2022-03-09 |
Family
ID=66476870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055799A MA55799A (fr) | 2019-04-30 | 2020-04-30 | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP3962475A1 (zh) |
| JP (2) | JP2022537877A (zh) |
| KR (2) | KR20220002488A (zh) |
| CN (2) | CN114269336A (zh) |
| AU (2) | AU2019443366A1 (zh) |
| BR (2) | BR112021021809A2 (zh) |
| CA (2) | CA3138473A1 (zh) |
| CL (1) | CL2021002847A1 (zh) |
| CO (2) | CO2021015614A2 (zh) |
| IL (2) | IL287665A (zh) |
| MA (1) | MA55799A (zh) |
| MX (2) | MX2021013317A (zh) |
| SG (2) | SG11202112043PA (zh) |
| WO (2) | WO2020222773A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019443366A1 (en) | 2019-04-30 | 2021-12-02 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| AU2022350509A1 (en) * | 2021-09-23 | 2024-04-04 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| WO2023076161A1 (en) | 2021-10-25 | 2023-05-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| WO2010129802A1 (en) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibitors of jak |
| CN103298794A (zh) | 2010-11-09 | 2013-09-11 | 塞尔卓姆有限公司 | 作为tyk2抑制剂的吡啶化合物及其氮杂类似物 |
| JP6022548B2 (ja) * | 2011-04-28 | 2016-11-09 | セルジーン コーポレイション | Ｐｄｅ４阻害剤を自己免疫疾患及び炎症性疾患の治療及び管理に使用する方法及び組成物 |
| EP2797581B1 (en) * | 2011-12-27 | 2020-05-06 | Amgen (Europe) GmbH | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
| CA2860547A1 (en) | 2012-01-10 | 2013-07-18 | Johannes Cornelius Hermann | Pyridazine amide compounds and their use as syk inhibitors |
| WO2013146963A1 (ja) | 2012-03-28 | 2013-10-03 | 武田薬品工業株式会社 | 複素環化合物 |
| EP2855451B1 (en) | 2012-05-24 | 2017-10-04 | Cellzome Limited | Heterocyclyl pyrimidine analogues as tyk2 inhibitors |
| HRP20220766T1 (hr) * | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| WO2014074670A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | ALKYL AMIDE-SUBSTITUTED PYRIMIDINE COMPOUNDS USEFUL IN THE MODULATION OF IL-12, IL-23 AND/OR IFNα |
| CN105050624A (zh) * | 2013-03-14 | 2015-11-11 | 细胞基因公司 | 利用阿普斯特来治疗银屑病关节炎的方法 |
| JPWO2015016206A1 (ja) | 2013-07-30 | 2017-03-02 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6239118B2 (ja) | 2013-09-03 | 2017-11-29 | サリウム リミテッド | 医薬化合物 |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| JP6458038B2 (ja) | 2013-12-10 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
| WO2015091584A1 (en) | 2013-12-18 | 2015-06-25 | F. Hoffmann-La Roche Ag | Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors |
| US9834548B2 (en) * | 2014-02-14 | 2017-12-05 | Portola Pharmaceuticals, Inc. | Pyridazine compounds as JAK inhibitors |
| AU2015222865B2 (en) | 2014-02-28 | 2019-06-20 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| EP3157520B1 (en) * | 2014-06-23 | 2019-09-04 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
| WO2016025686A1 (en) * | 2014-08-15 | 2016-02-18 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
| NO2721710T3 (zh) | 2014-08-21 | 2018-03-31 | ||
| WO2016047678A1 (ja) | 2014-09-25 | 2016-03-31 | 武田薬品工業株式会社 | 複素環化合物 |
| TWI744225B (zh) | 2015-02-27 | 2021-11-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶２（ｔｙｋ２）抑制劑及其用途 |
| TWI707852B (zh) | 2015-09-02 | 2020-10-21 | 美商林伯士拉克許米公司 | Tyk2 抑制劑及其用途 |
| AU2017222417B2 (en) | 2016-02-24 | 2020-07-09 | Pfizer Inc. | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as JAK-inhibitors |
| CN110036015B (zh) | 2016-10-07 | 2022-07-19 | 百时美施贵宝公司 | 可用作IL-12、IL-23和/或IFNα应答的调节剂的咪唑并哒嗪化合物 |
| CA3039202A1 (en) | 2016-10-14 | 2018-04-19 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| AU2017345736B2 (en) | 2016-10-21 | 2022-04-07 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| MA46620A (fr) | 2016-10-28 | 2021-05-26 | Bristol Myers Squibb Co | Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha |
| JP7012082B2 (ja) | 2016-11-17 | 2022-01-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎ－アルファのイミダゾピリダジン調節剤 |
| GB2562702B (en) | 2017-03-06 | 2022-05-18 | Linear Shaped Ltd | Frame and linear shaped charge |
| AU2018230737B2 (en) * | 2017-03-08 | 2022-09-22 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| AU2019443366A1 (en) | 2019-04-30 | 2021-12-02 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
-
2019
- 2019-04-30 AU AU2019443366A patent/AU2019443366A1/en not_active Abandoned
- 2019-04-30 CN CN201980097711.6A patent/CN114269336A/zh active Pending
- 2019-04-30 KR KR1020217038511A patent/KR20220002488A/ko unknown
- 2019-04-30 SG SG11202112043PA patent/SG11202112043PA/en unknown
- 2019-04-30 JP JP2021564469A patent/JP2022537877A/ja not_active Abandoned
- 2019-04-30 MX MX2021013317A patent/MX2021013317A/es unknown
- 2019-04-30 EP EP19723291.1A patent/EP3962475A1/en active Pending
- 2019-04-30 WO PCT/US2019/029772 patent/WO2020222773A1/en unknown
- 2019-04-30 CA CA3138473A patent/CA3138473A1/en active Pending
- 2019-04-30 BR BR112021021809A patent/BR112021021809A2/pt unknown
- 2019-04-30 IL IL287665A patent/IL287665A/en unknown
-
2020
- 2020-04-30 MA MA055799A patent/MA55799A/fr unknown
- 2020-04-30 CN CN202080046457.XA patent/CN114206333A/zh active Pending
- 2020-04-30 JP JP2021564471A patent/JP7453251B2/ja active Active
- 2020-04-30 AU AU2020266143A patent/AU2020266143A1/en active Pending
- 2020-04-30 CA CA3138686A patent/CA3138686A1/en active Pending
- 2020-04-30 WO PCT/US2020/030608 patent/WO2020223431A1/en unknown
- 2020-04-30 KR KR1020217038512A patent/KR20220002489A/ko unknown
- 2020-04-30 BR BR112021021826A patent/BR112021021826A8/pt unknown
- 2020-04-30 SG SG11202112018YA patent/SG11202112018YA/en unknown
- 2020-04-30 MX MX2021013318A patent/MX2021013318A/es unknown
- 2020-04-30 EP EP20725978.9A patent/EP3962476A1/en active Pending
-
2021
- 2021-10-28 IL IL287670A patent/IL287670A/en unknown
- 2021-10-29 CL CL2021002847A patent/CL2021002847A1/es unknown
- 2021-11-22 CO CONC2021/0015614A patent/CO2021015614A2/es unknown
- 2021-11-22 CO CONC2021/0015622A patent/CO2021015622A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220002488A (ko) | 2022-01-06 |
| CO2021015622A2 (es) | 2022-02-28 |
| EP3962475A1 (en) | 2022-03-09 |
| EP3962476A1 (en) | 2022-03-09 |
| BR112021021809A2 (pt) | 2022-01-04 |
| SG11202112018YA (en) | 2021-11-29 |
| AU2020266143A1 (en) | 2021-12-02 |
| IL287670A (en) | 2021-12-01 |
| AU2019443366A1 (en) | 2021-12-02 |
| CN114206333A (zh) | 2022-03-18 |
| CA3138686A1 (en) | 2020-11-05 |
| MX2021013317A (es) | 2022-01-18 |
| IL287665A (en) | 2022-07-01 |
| BR112021021826A8 (pt) | 2022-06-21 |
| MX2021013318A (es) | 2022-01-31 |
| KR20220002489A (ko) | 2022-01-06 |
| JP2022537878A (ja) | 2022-08-31 |
| CO2021015614A2 (es) | 2021-12-10 |
| BR112021021826A2 (pt) | 2022-01-04 |
| WO2020222773A1 (en) | 2020-11-05 |
| CL2021002847A1 (es) | 2022-07-22 |
| JP2022537877A (ja) | 2022-08-31 |
| CN114269336A (zh) | 2022-04-01 |
| WO2020223431A1 (en) | 2020-11-05 |
| CA3138473A1 (en) | 2020-11-05 |
| JP7453251B2 (ja) | 2024-03-19 |
| SG11202112043PA (en) | 2021-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55799A (fr) | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 | |
| IL282487A (en) | TYK2 inhibitors and their use | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| MA44890A (fr) | Compositions comprenant des souches bactériennes | |
| GB201909191D0 (en) | Therapeutic agents | |
| MA46716A (fr) | Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie | |
| IL286248A (en) | tyk2 inhibitors and their use | |
| IL284799A (en) | TYK2 inhibitors and uses thereof | |
| PH12021551282A1 (en) | Radioimmunoconjugates and checkpoint inhibitor combination therapy | |
| IL279810A (en) | Heteroaryl-converted sulfonamide compounds and their use as medicinal agents | |
| MD20160007A2 (ro) | Inhibitori ai RORC2 şi metode de utilizare a acestora | |
| IL276609A (en) | Combined treatment with epilimod and glutamatergic factors | |
| BR112017025998A2 (pt) | inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit | |
| MA47074A (fr) | Formes pharmaceutiques comprenant des inhibiteurs de canaux de task-1 et task-3 et leur utilisation pour le traitement des troubles respiratoires | |
| MA52165A (fr) | Inhibiteurs sélectifs de l'isoforme tgfbeta1 et utilisation associée | |
| GB201902277D0 (en) | Therapeutic agents | |
| ZA202100092B (en) | Modified cas9 protein and use thereof | |
| IL278949A (en) | Benzene sulfonamide compounds and their use as medicinal agents | |
| IL290217A (en) | Calling system and its use | |
| GB201906804D0 (en) | Therapeutic agents | |
| MA55816A (fr) | Combinaisons thérapeutiques comprenant des immunoconjugués anti-cd123 | |
| MA55781A (fr) | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 | |
| IL289531A (en) | cd38 binding agents and uses thereof | |
| IL288828A (en) | Binding factors - cd38 and their use | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies |